PGL4001
Phase 3Small molecule
PGL4001 is one of 16 small molecule programs targeting Uterine leiomyoma. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Uterine Leiomyoma
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Approved
Lupron
EEastern Cooperative Oncology Group
Approved
Dienogest
BayerApproved
Desogestrel
MMahidol University
Approved
Iron
WWatson Pharmaceuticals
Phase 3
N-Acetyl Cyteien
SStanford University
Phase 3
Esbriet
LLegacy Health System
Phase 2
Zocor
OOrganon and Co
Phase 2
Mifeprex
DDanco
Phase 2
Femara
NovartisPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PGL4001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPregLem SA